The government through the Ministry of Health continues to strive to achieve independence and realize the resilience of pharmaceutical preparations and medical devices in Indonesia by cooperating with the domestic pharmaceutical and medical device industries, so that the pharmaceutical industry is able to increase production capacity so as to meet domestic needs.

Currently, our domestic pharmaceutical industry can produce 8 of the 10 most widely used drug raw materials (BBO) in Indonesia, such as Paracetamol, Omeprazole, Atorvastatin, Clopidogrel, Amlodipine, Candesartan, Bisoprolol, and Azithromycin.

To encourage the use of domestically produced medicinal raw materials, the government facilitates a change in the source of imported raw materials with domestically produced medicinal raw materials for the pharmaceutical industry.

Through this change source facility, the government hopes to increase the use of domestically produced drug raw materials, reduce the number of imports of drug raw materials, and increase the number of drug products with a Domestic Content Level (TKDN) of more than 52 percent, which is a priority in procurement, especially for the procurement of government goods or services.

The program was launched by Minister of Health Budi G. Sadikin on June 2, 2022. As of June 2023, 38 pharmaceutical industries have been facilitated, especially for five domestic BBOs, namely Clopidogrel, Atorvastatin, Amlodipine, Candesartan, and Bisoprolol.

"Change source is the government's commitment to prioritize the use of domestic products and is a milestone in realizing the resilience of the pharmaceutical sector in the country, while still paying attention to the fulfillment of product requirements that are safe, quality, and efficacious," said Director General of Pharmaceuticals and Medical Devices L. Rizka Andalusia.

Dimas Ranggaditya, Business Development Manager of PT Kimia Farma Sungwun Pharmacopia expressed his appreciation for this change source program. He said that the increased utilization by the pharmaceutical industry will have an impact on drug prices which can be lower.

"This program is a breakthrough or incentive innovation and is a very effective government program in order to realize domestic pharmaceutical independence," Dimas added.

The country's pharmaceutical industry, which has been facilitated by Change Source, has greatly benefited from this program. Kurniawan Adi, Assistant Business Development Manager of PT Novell Pharmaceutical Laboratories welcomes this program and is committed to supporting it.

The government targets a 20 percent reduction in imports of drug raw materials from the change source of the 10 most widely used drug raw materials in Indonesia. So that the sustainability of this change source needs to be maintained by increasing accuracy and joint supervision.

With the active role of all stakeholders, the impact of change sources for health services and the community, through the availability of drugs with domestic raw materials, will be realized more quickly.

The Ministry of Health has once again proven its commitment to continue building the independence of pharmaceutical preparations through increasing the competitiveness of the pharmaceutical industry and domestically produced medicinal raw materials.